CB 008

Drug Profile

CB 008

Latest Information Update: 23 Dec 2014

Price : $50

At a glance

  • Originator Canopus BioPharma
  • Developer Canopus BioPharma; Texas Biomedical Research Institute; Unknown
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Ebola virus infections; Haemorrhage

Most Recent Events

  • 19 Dec 2014 Early research in Ebola virus infections and Haemorrhagic syndrome (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top